Privé Bastiaan M, Muselaers Constantijn H J, van Oort Inge M, Janssen Marcel J R, Peters Steffie M B, van Gemert Willemijn A M, Uijen Maike J M, Schilham Melline M G, Sedelaar J P Michiel, Westdorp Harm, Mehra Niven, Gotthardt Martin, Barentsz Jelle O, Gerritsen Winald R, Witjes J Alfred, Nagarajah James
Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands.
Department of Urology, Radboudumc, Nijmegen, Netherlands.
Front Nucl Med. 2022 May 3;2:863101. doi: 10.3389/fnume.2022.863101. eCollection 2022.
Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.
镥-PSMA-617放射性配体疗法是一种治疗晚期前列腺癌的新方法，也可应用于前列腺特异性膜抗原（PSMA）高表达的激素敏感性前列腺癌患者。从这个角度出发，我们回顾了镥-PSMA在低负荷转移性激素敏感性前列腺癌患者中的毒性、辐射剂量和治疗效果的近期研究结果。此外，我们还展示了参与该试验患者的长期随访数据，如毒性和无雄激素剥夺治疗（ADT）的时间。总体而言，在这种情况下以及长期随访中，镥-PSMA似乎是一种可行且安全的治疗方式。我们观察到前列腺特异性抗原（PSA）反应超过50%的男性似乎尤其能从这种治疗中受益，通过推迟ADT从而保持生活质量。
